- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03623607
Diabetes to Go: Inpatient Education Implementation (DM2GO)
Diabetes to Go Inpatient: A Study of the Implementation of a Technology-enabled Diabetes Survival Skills Education Program Within Medical-Surgical Nursing Unit Workflow
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators sought to determine the feasibility of integrating the Diabetes To Go inpatient DSSE program sustainably into ongoing hospital nursing unit processes for diabetes patient education and discharge planning. If successful, preliminary data generated will be used to develop a randomized controlled trial which will further assess program outcomes, including clinical and economic measures and potential for widespread dissemination.
The objectives of the R34 Diabetes To Go Inpatient proposal were to refine the Diabetes To Go program content based on user feedback and experience, as well as to design and develop processes to enhance the feasibility of integrated implementation within usual nursing unit workflow within one hospital belonging to a regional health system. A mixed-methods approach is used to leverage implementation science frameworks and human factors principles to make DSSE and discharge support more accessible, interactive and engaging for patients. The long-term goal of this research is to optimize scalable and sustainable solutions for DSSE delivery and for DM-related discharge support. This personalized approach leverages e-health technologies to pursue the following Specific Aims:
Aim 1: To refine and optimize the Diabetes To Go program content and implementation processes.
This will be achieved by applying user-centered interface design principles, content development in partnership with patients and providers, detailed process mapping for program integration into existing processes and workflow, and integrating mobile and e-health technology to support care transitions. The Practical, Robust, Implementation and Sustainability Model will guide implementation planning and evaluation.
Hypothesis 1. Diabetes To Go: will be optimized for patient and provider usability and integration into nursing unit workflow; will enhance patient self-care knowledge and skills; and will support the discharge transition process.
Aim 2: To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation.
This will be achieved by a series of intervention-evaluation cycles of field testing, refinement, retesting of the Diabetes To Go program and evaluation through: direct observation; patient, provider and system leadership stakeholder interviews and focus groups; and evaluation of changes in early patient outcomes.
Hypothesis 2. The Diabetes To Go program will be perceived favorably by stakeholders yielding a high-quality toolkit for implementation and delivery of the program for further evaluation and testing.
Preliminary data gathered during this study will be used to design an R18 pragmatic trial in response to PAR 15-157 which will examine outcomes of implementation of the Diabetes To Go program when delivered on hospital nursing units to adult patients with diabetes across multiple hospitals in a regional health system. The model has the potential to cause a paradigm shift in sustainable and generalizable approaches for delivery of patient-centered education and medication adherence and discharge transition support in the hospital.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients with diabetes on the selected units who meet the criteria above are eligible.
Among 596 T2DM patients identified on three medical-surgical units, 415 (70%) were program eligible (mean age 64 years, 57% male, 51% Black).
The criteria for inclusion were intentionally been kept broad to minimize disruption to unit workflow and to increase generalizability of findings. Where appropriate, the justification for each criteria is also presented, e.g. exclusion of minors.
Description
Inclusion Criteria:
- Age > 18 yrs (lower limit of age for admission to MWHC adult units. All of the Diabetes To Go content is designed for adult learners)
- English speaking (Diabetes To Go content is currently only available in English);
- Diagnosis of diabetes mellitus (ICD9 250.xx/ICD-10-CM E08-E11) documented in the EMR
- Admitted to one of the inpatient units (non-critical care adult medicine/surgery nursing units, including 1 psychiatry unit) where the study is being conducted
- Willing and able to participate in the program.
Exclusion criteria:
1. Age < 18 years (MWHC does not admit minors to its Medicine units and Diabetes To Go content has been prepared for adult learners) 2. Pregnancy or anticipated conception within 3 mos (Diabetes To Go content does not address gestational diabetes or diabetes in pregnancy where management and glycemic targets differ considerably from those for non-pregnant adults ); 3. Admission to an intensive-care unit, diabetic ketoacidosis, hyperglycemic hyperosmolar state - conditions in which the acuity level would likely preclude participation in DSME; 4. Patient declines participation in the education program for any reason; and any medical condition or cognitive dysfunction that, in the opinion of unit staff, would preclude participation in the education program.
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Integration of Diabetes Self Management Education and Support (DSMES) into nurses workflow
Time Frame: July 2016-May 2017 (11 months)
|
To identify and validate barriers and facilitators of reach, effectiveness, adoption, implementation and maintenance of a diabetes survival skills education program which is delivered at the bedside using a web-based e-learning platform by nursing unit staff to adult patients with type 2 diabetes prior to discharge from the hospital. Nursing unit staff (RN, patient care technician, clerical, leadership) provided input via focus groups and key informant interviews to inform intervention design. |
July 2016-May 2017 (11 months)
|
|
Patient acceptance of diabetes self-management education delivered via an e-learning platform.
Time Frame: November 2017 to March 2018 months
|
Rates of patient engagement with the DSMES program via the e-learning platform.
|
November 2017 to March 2018 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To conduct iterative rapid-cycle usability testing of the enhanced Diabetes To Go program content and processes and establish a Diabetes To Go program toolkit for widespread implementation
Time Frame: May 2017 to Oct 2017 months
|
This will be achieved by a series of intervention-evaluation cycles of field testing, refinement, retesting of the Diabetes To Go program and evaluation through: direct observation; patient, provider and system leadership stakeholder interviews and focus groups; and evaluation of changes in early patient outcomes.
|
May 2017 to Oct 2017 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implementation effectiveness evaluation
Time Frame: February 2018 - October 2018 (6 months)
|
Implementation effectiveness evaluation will be guided by the RE-AIM framework.
Our approach considers differences in hospital and nursing workflow, patient characteristics and is sensitive to differences in patient culture, knowledge and beliefs.
Our mixed methods approach to operationalizing the RE-AIM framework used both qualitative and quantitative outcomes at the setting, staff, and patient levels.
|
February 2018 - October 2018 (6 months)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-019
- 1R34DK109503-01 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Diabetes Survival Skills Education
-
Medstar Health Research InstituteSanofiCompletedHyperglycemia | Diabetes Mellitus
-
Medstar Health Research InstituteSanofi; Bayer; American Diabetes AssociationCompletedDiabetes Mellitus, Type 2 | Medication Adherence | HYPERGLYCEMIAUnited States
-
University of ConnecticutAmerican Nurses FoundationCompleted
-
Indiana UniversityEli Lilly and CompanyCompletedType 1 Diabetes | Adolescent BehaviorUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)Completed
-
Medstar Health Research InstituteCompletedType 2 Diabetes MellitusUnited States
-
Vanderbilt UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 2 DiabetesUnited States
-
Tokat Gaziosmanpasa UniversityCompletedStigmatization | Functionality | Peer Support | Chronic Mental Disorders | Psychosocial Skills Training | InsightTurkey
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingDiabetes Mellitus, Type 2American Samoa
-
Federal University of Minas GeraisUnknownType 2 Diabetes MellitusBrazil